We are live on ! Find out more
BCLSI

Bain Capital Life Sciences Investors Portfolio holdings

AUM $1.11B
1-Year Est. Return 171.34%
This Fund
S&P 500
This Quarter Est. Return
-19.01%
1 Year Est. Return
+171.34%
3 Year Est. Return
+643.23%
5 Year Est. Return
+451.99%
10 Year Est. Return
–
AUM
$911M
AUM Growth
-$333M
Cap. Flow
-$41.3M
Cap. Flow %
-4.53%
Top 10 Hldgs %
87.82%
Holding
27
New
1
Increased
6
Reduced
4
Closed
2

Top Buys

Rank Stock Value
1
IPSC icon
Century Therapeutics
IPSC
+$17.1M
2
IRON icon
Disc Medicine
IRON
+$16.3M
3
KYTX icon
Kyverna Therapeutics
KYTX
+$3.12M
4
MRNS
Marinus Pharmaceuticals, Inc
MRNS
+$2.19M
5
XLO icon
Xilio Therapeutics
XLO
+$1.1M

Top Sells

Rank Stock Value
1
MDGL icon
Madrigal Pharmaceuticals
MDGL
+$52.6M
2
NRIX icon
Nurix Therapeutics
NRIX
+$16.6M
3
ARQT icon
Arcutis Biotherapeutics
ARQT
+$8.87M
4
ACRS icon
Aclaris Therapeutics
ACRS
+$2.35M
5
ANNX icon
Annexon
ANNX
+$1.31M

Sector Composition

Rank Sector Weight
1 Healthcare 99.61%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
MDGL icon
26
Madrigal Pharmaceuticals
MDGL
$12.4B
– –
-196,995
Closed -$52.6M
NRIX icon
27
Nurix Therapeutics
NRIX
$2.76B
– –
-1,132,397
Closed -$16.6M
1
2

Similar funds

JTWM
Jackson Thornton Wealth Management Montgomery, Alabama $1.11B AUM 22.53% 1-Year Est. Return
HH
Hilltop Holdings Dallas, Texas $1.11B AUM 24.7% 1-Year Est. Return
RIM
Rockbridge Investment Management Syracuse, New York $1.11B AUM 13.62% 1-Year Est. Return
YL
YCG LLC Austin, Texas $1.1B AUM 4.87% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return
AIM
Advyzon Investment Management Lisle, Illinois $1.12B AUM 22.08% 1-Year Est. Return
MTCM
Mint Tower Capital Management Amsterdam, Netherlands $1.12B AUM 18.84% 1-Year Est. Return
CNC
Canandaigua National Corp Canandaigua, New York $1.12B AUM

Bain Capital Life Sciences Investors's Q2 2024 Portfolio in Review

As of Q2 2024, Bain Capital Life Sciences Investors held 27 positions worth $911M, down 27% from $1.24B the previous quarter. Its ten largest holdings account for 88% of the portfolio.

Bain Capital Life Sciences Investors withdrew a net $41.3M in Q2 2024, closing 2 positions and reducing 4 holdings. Its most notable exit was Madrigal Pharmaceuticals, an estimated $52.6M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 99% a quarter earlier.

Against the trend, Bain Capital Life Sciences Investors opened a new position in Century Therapeutics worth $13.8M.

  • Bain Capital Life Sciences Investors's largest Q2 2024 buy was Century Therapeutics: 5,410,361 shares worth $13.8M.
  • Bain Capital Life Sciences Investors added most to Disc Medicine in Q2 2024, an estimated $16.3M increase.
  • Bain Capital Life Sciences Investors's biggest Q2 2024 reduction was Arcutis Biotherapeutics, cutting an estimated $8.87M.
  • Bain Capital Life Sciences Investors fully exited Madrigal Pharmaceuticals in Q2 2024, selling an estimated $52.6M.
  • Bain Capital Life Sciences Investors's ten largest holdings make up 88% of its $911M portfolio in Q2 2024.
  • Bain Capital Life Sciences Investors opened 1 new position and closed 2 in Q2 2024.
  • Bain Capital Life Sciences Investors's portfolio value fell 27% quarter-over-quarter to $911M.

Based on Bain Capital Life Sciences Investors's 13F filing for Q2 2024, filed 12 Aug 2024.